Diagnosis and Management of Dementia
JAMA 322:1589-1599, Arvanitakis, Z.,et al, 2019
International Consensus Guidance for Management of Myasthenia Gravis
Neurol 87:419-425, Sanders, D.B.,et al, 2016
Efficacy and Safety of Cholinesterase Inhibitors and Memantine in Cognitive Impairment in Parkinsons Disease, Parkinsons Disease Dementia, and Dementia with Lewy Bodies: Systematic Review with Meta-Analysis and Trial Sequential Analysis
JNNP 86:135-143, Wang, H.F.,et al, 2015
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
CBRNE - Nerve Agents, V-series - Ve, Vg, Vm, Vx
emedicine Feb, Keyes, D.C. & Caneva, D.C., 2015
Degenerative Diseases of the Nervous System, Alzheimer Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1063, Ropper, A.H.,et al, 2014
Myasthenia Gravis
BMJ 345:e8497, Spillane, J.,et al, 2012
Early Alzheimers Disease
NEJM 362:2194-2201, Mayeux,R., 2010
Alzheimers Disease
BMJ 338:467-471, Burns,A. &Iliffe,S., 2009
A 60-Year-Old Woman with Mild Memory Impairment: Review of Mild Cognitive Impairment
JAMA 300:1566-1574,1598, Ellison,J.M., 2008
Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review)
Neurol 66:996-1002, Miyasaki,J.M.,et al, 2006
Pharmacological treatment of Neuropsychiatric Symptoms of Dementia
JAMA 293:596-608, Sink,K.M.,et al, 2005
Therapy for Nerve Agent Poisoning
Arch Neurol 61:649-652, Newmark,J., 2004
Size of the Treatment Effect on Cognition of Cholinesterase Inhibition in Alzheimer's Disease
JNNP 75:677-685, Rockwood,K., 2004
Alzheimer's Disease
NEJM 351:56-67, Cummings,J.L, 2004
Management of Myasthenia Gravis
Semin Neurol 24:41-48, Saperstein,D.S. &Barohn,R.J., 2004
Efficacy of Cholinesterase Inhibitors in the Treatment of Neuropsychiatric symptoms and Functional Impairment in Alzheimer Disease
JAMA 289:210-216, Trinh,N.,et al, 2003
Ten Most Commonly Asked Questions About the Psychiatric Aspects of Parkinson's Disease
The Neurologist 9:50-56, Reich,S.G. & Marsh,L., 2003
Treatment of Autoimmune Myasthenia Gravis
Neurol 61:1652-1661, Richman,D.P. & Agius,M.A., 2003
Drugs for Alzheimer's Disease
BMJ 323:123-124, O'Brien,J.T . &Ballard,C.G., 2001
Galantamine (Reminyl) for Alzheimer's Disease
Medical Letter 43:53-54, , 2001
An 80-Year-Old Man With Memory Loss
JAMA 283:1046-1053, Larson,E.B., 2000
Rivastigmine (Exelon) for Alzheimer's Disease
The Medical Letter 42:93-94, , 2000
A 5-Month, Randomized, Placebo-controlled Trial of Galantamine in AD
Neurol 54:2269-2276, Tariot,P.N.,et al, 2000
Galantamine in AD
Neurol 54:2261-2268, Raskind,M.A.,et al, 2000
Treatment of Alzheimer's Disease
NEJM 341:1670-1679, Mayeux,R.&Sano,M, 1999
Pharmacologic Treatment of Cognition in Alzheimer's Dementia
Neurol 51:S36-S44, Farlow,M.R.&Evans,R.M., 1998
Self-Reported Exposure to Neurotoxic Chemical Combinations in the Gulf War:A Cross-Sectional Epidemiologic Study
JAMA 227:231-237, 2591997., Haley,R.W.&Kurt,T.L., 1997
Donepezil (Aricept) for Alzheimer's Disease
The Medical Letter 39:53-54, , 1997
Treatment of Acquired Myasthenia Gravis
Neurol 48 (Suppl 5) :S46-S51997., Massey,J.M., 1997
An Update on Primary Drug Therapies for Alzheimer Disease
Arch Neurol 54:1406-1409, Knopman,D.S.&Morris,J.C., 1997
Diagnosis and Treatment of Alzheimer Disease and Related Disorders
JAMA 278:1363-1371, Small,G.W.,et al, 1997
Tacrine
Lancet 345:625-630, Davis,K.L.&Powchik,P., 1995
Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Nerve Agents:A Review
Neurol 42:946-950, Gunderson,C.H.,et al, 1992
Drug-Induced Seizures:A 10-Year Experience
Neurol 34:1582-1586, Messing,R.O.,et al, 1984